AR036183A1 - 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula - Google Patents
1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomoleculaInfo
- Publication number
- AR036183A1 AR036183A1 ARP020102719A ARP020102719A AR036183A1 AR 036183 A1 AR036183 A1 AR 036183A1 AR P020102719 A ARP020102719 A AR P020102719A AR P020102719 A ARP020102719 A AR P020102719A AR 036183 A1 AR036183 A1 AR 036183A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- group
- atoms
- radical
- optionally
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 9
- -1 C1-4 alkyl radical Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 3
- 150000003254 radicals Chemical class 0.000 abstract 3
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004185 ester group Chemical group 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 abstract 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical class C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940039231 contrast media Drugs 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003439 radiotherapeutic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen 1,4,7,10-tetraazaciclododecanos, de fórmula (1), donde Z representa un átomo de hidrógeno o al menos dos Z representan un equivalente de un ión metálico; B representa un átomo de hidrógeno o un radical alquilo C1-4; R representa un átomo de hidrógeno o un radical alquilo C1-10 o arilo lineal, ramificado o cíclico, saturado o insaturado que está sustituido opcionalmente por un grupo carboxilo, -SO3H ó -PO3H2, y donde la cadena de alquilo del radical alquilo C1-10 contiene opcionalmente un grupo arilo y/o 1-2 átomos de oxígeno, con la condición de que los radicales B y R no representen al mismo tiempo átomos de oxígeno; A representa una cadena de hidrocarburos C1-30 lineal o ramificada, saturada o insaturada, que contiene opcionalmente 1-5 átomos de oxígeno, 1-5 átomos de nitrógeno y/o 1-5 radicales -NR', donde R' está definido como R, pero que puede seleccionarse de modo independiente, que está opcionalmente sustituido con 1-3 grupos carboxilo, 1-3 -SO3H, 1-3 -PO3H2 y/o 1-3 átomos de halógeno, donde están presentes opcionalmente 1-3 átomos de carbono como grupos carbonilo, donde la cadena o una parte de la cadena puede estar dispuesta en forma de anillo, y que está conformada de modo tal que X está enlazado al menos a través de 3 átomos con el átomo de nitrógeno al que está unido A; X representa un grupo que puede reaccionar con una biomolécula, y sus sales, con la condición de que, (a) cuando B es un átomo de hidrógeno y R es -CH2CH2CO2H, A-X juntos no son -CH(CO2H)CH2CH2CO2H; (b) cuando B es un átomo de hidrógeno y R es un radical metilo o etilo que eventualmente está sustituido por un grupo carboxilo, A no representa el radical -CH(R4)-CO-NR2-U6, donde R2 es un átomo de hidrógeno o un radical metilo o etilo que eventualmente está sustituido por un grupo carboxilo; R4 es una cadena alquilo C1-30 lineal o ramificada, saturada o insaturada que eventualmente puede estar interrumpida por 1-10 átomos de oxígeno, un grupo fenileno, un grupo fenilenoxi o eventualmente sustituida por 1-5 grupos hidroxi, 1-3 grupos carboxi, 1 grupo fenilo y U6 es un grupo alquileno C1-20 lineal o ramificado, saturado o insaturado que contiene eventualmente 1-5 grupos imino, 1-3 grupos fenileno, 1-3 grupos fenilenoxi, 1-3 grupos fenilenimino, 1-5 grupos amida, 1-2 grupos hidracida, 1-5 grupos carbonilo, 1-5 grupos etilenoxi, 1 grupo urea, un grupo tiourea, 1-2 grupos carboxialquilimino, 1-2 grupos éster; 1-10 átomos de oxígeno, 1-5 átomos de azufre y/o 1-5 átomos de nitrógeno y/o eventualmente sustituido por 1-5 grupos hidroxi, 1-2 grupos mercapto, 1-5 grupos oxo, 1-5 grupos tioxo, 1-3 grupos carboxi, 1-5 grupos carboxialquilo, 1-5 grupos éster, y/o 1-3 grupos amino, donde los grupos fenileno eventualmente contenidos pueden estar sustituidos por 1-2 grupos carboxi, 1-2 grupos sulfo o 1-2 grupos hidroxi, y (c) cuando B es un hidrógeno y R es un radical alquilo C1-4, A no es el radical -CHR3-C(O)-NH-(CH2)1-6-NH-D- donde R3 es un átomo de hidrógeno o un radical alquilo C1-4, D es un grupo alquileno C1-4, de cadena lineal o ramificada, saturado o insaturado, que opcionalmente puede estar interrumpido o sustituido por un grupo carbonilo y D está unido a X. Procedimiento para obtener los compuestos de la fórmula (1) y uso de estos últimos para obtener un conjugado con una biomolécula. Estos conjugados son aptos como medios de contraste en el diagnóstico por RMN y radiodiagnóstico y como sustancia radioterapéutica. Con los ligandos especiales de macrociclo 1,4,7,10-tetraazaciclododecano se logra una elevada relajación y se posibilita un ajuste fino de la relajación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10135356A DE10135356C1 (de) | 2001-07-20 | 2001-07-20 | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036183A1 true AR036183A1 (es) | 2004-08-18 |
Family
ID=7692471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102719A AR036183A1 (es) | 2001-07-20 | 2002-07-19 | 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7164016B2 (es) |
| EP (1) | EP1409024B1 (es) |
| JP (1) | JP2005504745A (es) |
| KR (1) | KR20040030826A (es) |
| CN (1) | CN1533286A (es) |
| AR (1) | AR036183A1 (es) |
| AT (1) | ATE403442T1 (es) |
| AU (1) | AU2002321236B2 (es) |
| BR (1) | BR0211273A (es) |
| CA (1) | CA2453106A1 (es) |
| DE (2) | DE10135356C1 (es) |
| IL (1) | IL159290A0 (es) |
| MX (1) | MXPA04000401A (es) |
| NO (1) | NO20040238L (es) |
| PE (1) | PE20030322A1 (es) |
| PL (1) | PL366426A1 (es) |
| RU (1) | RU2305096C2 (es) |
| UY (1) | UY27390A1 (es) |
| WO (1) | WO2003009874A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
| DE10325752A1 (de) * | 2003-06-06 | 2004-12-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Lektin-Konjugate |
| US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
| WO2006114738A2 (en) * | 2005-04-26 | 2006-11-02 | Koninklijke Philips Electronics N.V. | Mri contrast agents comprising cest active paramagnetic complex |
| FI20055712A0 (fi) * | 2005-12-29 | 2005-12-29 | Wallac Oy | Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit |
| JP2009534381A (ja) * | 2006-04-19 | 2009-09-24 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 細胞画像化および治療のための組成物および方法 |
| US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| WO2010011367A2 (en) * | 2008-02-22 | 2010-01-28 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
| US10556873B2 (en) | 2008-02-22 | 2020-02-11 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
| KR101253100B1 (ko) * | 2010-02-16 | 2013-04-10 | 경북대학교 산학협력단 | 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 |
| KR101236142B1 (ko) * | 2010-09-30 | 2013-02-21 | 경북대학교 산학협력단 | 가돌리늄 착물을 함유하는 ｍｒｉ조영제 |
| WO2015051362A1 (en) | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
| EP3101012A1 (en) * | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| JP7034160B2 (ja) | 2016-11-28 | 2022-03-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物 |
| IL313115A (en) | 2017-05-05 | 2024-07-01 | Centre For Probe Dev And Commercialization | R1–IGF monoclonal antibodies and their use |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| JP2020518673A (ja) | 2017-05-05 | 2020-06-25 | フュージョン・ファーマシューティカルズ・インコーポレイテッド | 二官能性キレートの薬物動態増強及びその使用 |
| FR3069245B1 (fr) * | 2017-07-21 | 2019-07-26 | Guerbet | Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales |
| CN109810140B (zh) * | 2017-11-22 | 2021-06-29 | 湖南科技大学 | 一种血红素配体模拟物及其合成方法 |
| PE20211471A1 (es) | 2018-11-23 | 2021-08-05 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos |
| CN110396122B (zh) * | 2019-08-13 | 2020-10-27 | 牡丹江医学院 | 一种核磁共振造影剂、制备方法及其用于肿瘤诊断中的用途 |
| KR102203368B1 (ko) * | 2020-10-30 | 2021-01-14 | 경북대학교 산학협력단 | 신규한 화합물 및 이를 함유하는 mri 조영제 |
| EP4059925A1 (en) * | 2021-03-15 | 2022-09-21 | Bayer Aktiengesellschaft | New contrast agent for use in magnetic resonance imaging |
| CN115364684B (zh) * | 2022-10-25 | 2023-01-03 | 天津大学 | 一种高通量荷正电纳滤膜及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132409A (en) * | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
| US5049667A (en) * | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
| US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
| GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| NZ229700A (en) * | 1988-06-24 | 1993-01-27 | Dow Chemical Co | Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments |
| US5972307A (en) * | 1989-10-23 | 1999-10-26 | Nycomed Salutar, Inc. | Dichelants |
| JPH04154729A (ja) * | 1990-10-16 | 1992-05-27 | Nippon Mejifuijitsukusu Kk | 磁気共鳴造影剤 |
| US5133956A (en) * | 1991-05-30 | 1992-07-28 | The Dow Chemical Company | Radiolabeled metal-binding protein for the treatment of arthritis |
| JPH0656802A (ja) * | 1992-03-27 | 1994-03-01 | Nippon Mejifuijitsukusu Kk | テトラアザシクロドデカン誘導体およびその用途 |
| AU663572B2 (en) | 1992-03-27 | 1995-10-12 | Nihon Medi-Physics Co., Ltd. | Tetraazacyclododecane derivative and its use |
| FR2689739B1 (fr) * | 1992-04-10 | 1994-07-08 | Europ Sieges Automobiles | Siege perfectionne a positions multiples. |
| US5310535A (en) * | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
| IT1265440B1 (it) * | 1993-12-24 | 1996-11-22 | Bracco Spa | Formulazioni diagnostiche paramagnetiche e metodo d'uso delle stesse |
| ATE199550T1 (de) * | 1993-12-30 | 2001-03-15 | Guerbet Sa | Polyaminierte liganden, metallkomplexe, verfahren zur herstellung und diagnostische und therapeutische verwendungen |
| US6693190B1 (en) * | 1994-05-11 | 2004-02-17 | Bracco International B.V. | Enhanced relaxivity monomeric and multimeric compounds |
| DE19525924A1 (de) | 1995-07-04 | 1997-01-09 | Schering Ag | Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| DE19603033A1 (de) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
| CA2269335C (en) * | 1996-10-21 | 2010-05-25 | Quadrant Healthcare (Uk) Limited | Platelet substitutes and conjugation methods suitable for their preparation |
| IT1291624B1 (it) * | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
| IT1293777B1 (it) * | 1997-07-25 | 1999-03-10 | Bracco Spa | Processo per la preparazione di tetraazamacrocicli |
| IT1293778B1 (it) * | 1997-07-25 | 1999-03-10 | Bracco Spa | 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli |
| US6019959A (en) * | 1997-07-31 | 2000-02-01 | Schering Aktiengesellschaft | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis |
| WO2001052900A2 (en) * | 2000-01-21 | 2001-07-26 | Mallinckrodt Inc. | Novel orthogonally protected amino acid chelators for biomedical applications |
| DE10135355C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
| DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
-
2001
- 2001-07-20 DE DE10135356A patent/DE10135356C1/de not_active Expired - Fee Related
-
2002
- 2002-07-17 UY UY27390A patent/UY27390A1/es not_active Application Discontinuation
- 2002-07-18 IL IL15929002A patent/IL159290A0/xx unknown
- 2002-07-18 PL PL02366426A patent/PL366426A1/xx not_active Application Discontinuation
- 2002-07-18 MX MXPA04000401A patent/MXPA04000401A/es unknown
- 2002-07-18 JP JP2003515266A patent/JP2005504745A/ja active Pending
- 2002-07-18 CA CA002453106A patent/CA2453106A1/en not_active Abandoned
- 2002-07-18 KR KR10-2004-7000906A patent/KR20040030826A/ko not_active Application Discontinuation
- 2002-07-18 BR BR0211273-6A patent/BR0211273A/pt not_active IP Right Cessation
- 2002-07-18 AU AU2002321236A patent/AU2002321236B2/en not_active Ceased
- 2002-07-18 AT AT02754904T patent/ATE403442T1/de not_active IP Right Cessation
- 2002-07-18 WO PCT/EP2002/007999 patent/WO2003009874A1/de active IP Right Grant
- 2002-07-18 RU RU2004105261/04A patent/RU2305096C2/ru not_active IP Right Cessation
- 2002-07-18 CN CNA028145704A patent/CN1533286A/zh active Pending
- 2002-07-18 DE DE50212604T patent/DE50212604D1/de not_active Expired - Fee Related
- 2002-07-18 EP EP02754904A patent/EP1409024B1/de not_active Expired - Lifetime
- 2002-07-19 PE PE2002000642A patent/PE20030322A1/es not_active Application Discontinuation
- 2002-07-19 US US10/198,046 patent/US7164016B2/en not_active Expired - Fee Related
- 2002-07-19 AR ARP020102719A patent/AR036183A1/es unknown
-
2004
- 2004-01-19 NO NO20040238A patent/NO20040238L/no not_active Application Discontinuation
-
2006
- 2006-03-28 US US11/390,472 patent/US20070009442A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004105261A (ru) | 2005-07-10 |
| PE20030322A1 (es) | 2003-04-13 |
| US20070009442A1 (en) | 2007-01-11 |
| IL159290A0 (en) | 2004-06-01 |
| CN1533286A (zh) | 2004-09-29 |
| JP2005504745A (ja) | 2005-02-17 |
| KR20040030826A (ko) | 2004-04-09 |
| AU2002321236B2 (en) | 2006-11-02 |
| ATE403442T1 (de) | 2008-08-15 |
| MXPA04000401A (es) | 2004-03-18 |
| BR0211273A (pt) | 2004-08-03 |
| EP1409024B1 (de) | 2008-08-06 |
| UY27390A1 (es) | 2003-02-28 |
| US20030108486A1 (en) | 2003-06-12 |
| NO20040238L (no) | 2004-01-19 |
| DE10135356C1 (de) | 2003-04-17 |
| EP1409024A1 (de) | 2004-04-21 |
| US7164016B2 (en) | 2007-01-16 |
| PL366426A1 (en) | 2005-01-24 |
| RU2305096C2 (ru) | 2007-08-27 |
| CA2453106A1 (en) | 2003-02-06 |
| DE50212604D1 (de) | 2008-09-18 |
| WO2003009874A1 (de) | 2003-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036183A1 (es) | 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula | |
| AR036182A1 (es) | Conjugados de biomoleculas y 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion, su uso para la preparacion de medios de diagnostico por resonancia magnetica nuclear o radiodiagnostico o para la radioterapia, los agentes farmaceuticos que los contienen, y los conjuntos o kits para | |
| AR023260A1 (es) | Peptidos macrociclicos activos frente al virus de la hepatitis c. | |
| AR015906A1 (es) | Compuesto derivado de fenilo o piridilo, composicion farmaceutica que lo contiene y su uso en la preparacion de un medicamento | |
| KR950017976A (ko) | 폴리아미노화 리간드와 이의 금속착염 | |
| AR036213A1 (es) | Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas | |
| ATE144522T1 (de) | Polyazamakrocyclische verbindungen für komplexierung metal-ionen | |
| ATE121082T1 (de) | Tri-azamakrozyklen und deren metall komplexe. | |
| DK393387A (da) | Makrocykliske forbindelser | |
| ES2052767T3 (es) | Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen. | |
| ES444523A1 (es) | Un procedimiento para preparar nuevos derivados de benzo- triazol. | |
| ATE165095T1 (de) | Heterocyclische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ATE19251T1 (de) | Hemmer der kollagenase der saeugetiere. | |
| Kalvoda et al. | Polarographic analysis of solutions containing adsorbable complexes | |
| EA200001165A1 (ru) | Производные тетрагидрохинолина в качестве антагонистов глицина | |
| ATE82505T1 (de) | Absorptionsverbesserer. | |
| FI895937A0 (fi) | Nya imidazolidinderivat, foerfaranden foer deras framstaellning samt laekemedel innehaollande dessa foereningar. | |
| NO930068D0 (no) | Nye kjemiske forbindelser | |
| ATE127492T1 (de) | Für photovernetzungsprozesse geeignete carbonylgruppenhaltige polyphosphazenderivate. | |
| MX173423B (es) | DERIVADOS DE 1-ARILSULFINIL-2-PIRROLIDINONA Y P ROCEDIMIENTO PARA SU PREPARACION R1, donde R1, en cualquier posición sobre el núcleR3 donde R2 y R3, identicos o difernetes represent | |
| Battistuzzi et al. | Fe3+ binding to ovotransferrin in the presence of α-amino acids | |
| ATE147747T1 (de) | Platin(ii)-komplex und antitumormittel | |
| AR055200A1 (es) | Complejos metalicos con contenido de perfluoroalquilo procedimientos para su preparacion, asi como su uso | |
| Kempf et al. | The allosteric effector molecule 2, 3-bisphosphoglycerate as a function of protonation in aqueous solutions—an FT-IR study | |
| ES427592A1 (es) | Procedimiento para preparar amidas del acido dihidroapovin-caminico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |